Patents by Inventor Thomas Borglum Kjeldsen
Thomas Borglum Kjeldsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9260502Abstract: The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.Type: GrantFiled: March 13, 2009Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
-
Patent number: 9260501Abstract: Insulins to which there is connected an amino acid oligomer have satisfactory properties.Type: GrantFiled: October 29, 2007Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Thomas Høeg-Jensen, Thomas Børglum Kjeldsen, Jan Markussen
-
Patent number: 9242011Abstract: Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.Type: GrantFiled: March 31, 2009Date of Patent: January 26, 2016Assignee: Novo Nordisk A/SInventors: Tina Møller Tagmose, Peter Madsen, Thomas Børglum Kjeldsen
-
Patent number: 9150633Abstract: An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.Type: GrantFiled: August 15, 2008Date of Patent: October 6, 2015Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Børglum Kjeldsen, Thomas Hoeg-Jensen, Tina Møller Tagmose, Palle Jakobsen, János Tibor Kodra, Patrick William Garibay, Dorte Xenia Gram
-
Patent number: 8987197Abstract: Novel PEGylated insulin analogs exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogs contain B25H and A14E or A14H. The PEGylation is at B29K.Type: GrantFiled: November 29, 2011Date of Patent: March 24, 2015Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
-
Patent number: 8883449Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.Type: GrantFiled: October 15, 2008Date of Patent: November 11, 2014Assignee: Novo Nordisk A/SInventors: Thomas Børglum Kjeldsen, Morten Schlein, Anders Robert Sørensen, Peter Madsen
-
Patent number: 8835132Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.Type: GrantFiled: August 18, 2009Date of Patent: September 16, 2014Assignee: Novo Nordisk A/SInventors: Ib Jonassen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
-
Patent number: 8722620Abstract: The present invention is related to insulin derivatives having a side chain attached to an ?-amino group of a Lys residue present in the A-chain or to an ?-amino group of a Lys residue in the B-chain.Type: GrantFiled: February 27, 2007Date of Patent: May 13, 2014Assignee: Novo Nordisk A/SInventors: Charlotte Harkjaer Fynbo, Ib Jonassen, Thomas Børglum Kjeldsen, Peter Madsen, Patrick William Garibay, Janos Tibor Kodra, Thomas Hoeg-Jensen, Tina Møller Tagmose
-
Patent number: 8710001Abstract: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.Type: GrantFiled: September 2, 2011Date of Patent: April 29, 2014Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Børglum Kjeldsen, Tina Møller Tagmose, Palle Jakobsen
-
Patent number: 8575096Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: GrantFiled: August 12, 2008Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Publication number: 20120071402Abstract: Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
-
Patent number: 8129146Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.Type: GrantFiled: April 17, 2008Date of Patent: March 6, 2012Assignee: Novo Nordisk A/SInventors: Thomas Borglum Kjeldsen, Svend Ludvigsen
-
Publication number: 20110319591Abstract: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.Type: ApplicationFiled: September 2, 2011Publication date: December 29, 2011Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Børglum Kjeldsen, Tina Møller Tagmose, Palle Jackobsen
-
Publication number: 20110294729Abstract: Insulin analogues wherein the B25 amino acid residue is His or Asn with the proviso that if the B25 amino acid residue is His, then the B27 amino acid residue is Asp or Glu and the A14 amino acid residue is different from Glu, have liver preferential actions.Type: ApplicationFiled: December 3, 2009Publication date: December 1, 2011Applicant: Novo Nordisk A/SInventors: Carsten Enggaard Stidsen, Tine Glendorf, Thomas Börglum Kjeldsen
-
Publication number: 20110105720Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: ApplicationFiled: March 13, 2009Publication date: May 5, 2011Inventors: Peter Madsen, Thomas Børglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Møller Tagmose, Tine Glendorf, Jånos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
-
Publication number: 20110098439Abstract: Acylated insulins wherein an acyl moiety is attached to the parent insulin and wherein said acyl moiety comprises repeating units of alkylene glycol containing amino acids and wherein there is only one lysine residue (K & Lys) in the parent insulin have satisfactory properties when administered pulmonary.Type: ApplicationFiled: August 15, 2008Publication date: April 28, 2011Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Børglum Kjeldsen, János Tibor Kodra, Dorte Xenia Gram
-
Publication number: 20110092419Abstract: The present invention relates to novel insulin analogues comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogues; insulin preparations containing the insulin analogues of the invention; and, a method of treating diabetes mellitus using these insulin analogues.Type: ApplicationFiled: March 19, 2009Publication date: April 21, 2011Applicant: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
-
Publication number: 20110039769Abstract: Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.Type: ApplicationFiled: March 31, 2009Publication date: February 17, 2011Applicant: Novo Nordisk A/SInventors: Tina Møller Tagmose, Peter Madsen, Thomas Børglum Kjeldsen
-
Publication number: 20110021423Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: ApplicationFiled: August 12, 2008Publication date: January 27, 2011Applicant: NOVO NORIDSK A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Publication number: 20110009314Abstract: The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin.Type: ApplicationFiled: September 17, 2010Publication date: January 13, 2011Applicant: Novo Nordisk A/SInventors: Helle Naver, Thomas Børglum Kjeldsen